Aclarion Grants Inducement Stock Option to New Western U.S. Commercial Director Amid Growing Demand for Nociscan

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced on May 6, 2026, that its compensation committee granted an inducement stock option to Daniel Keefe, the company’s recently hired Commercial Director for the Western United States. The option to purchase 17,000 shares of common stock at an exercise price of $3.20 per share was granted on May 5, 2026, as a material inducement for Keefe to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

The grant reflects Aclarion’s strategic expansion of its commercial team in response to what the company describes as ‘increasing demand for Nociscan, supported by triple-digit growth in utilization.’ Nociscan is a SaaS platform that uses magnetic resonance spectroscopy, biomarkers, and proprietary augmented intelligence algorithms to help physicians noninvasively identify painful lumbar discs, potentially improving treatment outcomes for chronic low back pain.

According to the terms of the inducement grant, one-fourth of the options vest on the one-year anniversary of the vesting commencement date, with the remainder vesting in equal monthly installments over the subsequent three years, contingent on Keefe’s continued employment. The options carry a 10-year term and are subject to a standard inducement stock option agreement.

This hiring and stock grant come at a pivotal time for Aclarion as it scales its commercial operations. The company’s focus on the chronic low back pain market, which affects millions of patients annually, positions Nociscan as a potential tool to reduce unnecessary surgeries and improve treatment precision. By distinguishing painful from nonpainful discs, the platform aims to provide physicians with critical insights to optimize treatment strategies.

Aclarion’s forward-looking statements in the press release caution that the company’s expectations regarding demand for Nociscan are subject to risks and uncertainties, detailed in its filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025.

For more information about Aclarion and Nociscan, visit www.aclarion.com. The latest news and updates relating to $ACON are available in the company’s newsroom at https://tinyurl.com/aconnewsroom.

This news story relied on content distributed by PRISM Mediawire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Aclarion Grants Inducement Stock Option to New Western U.S. Commercial Director Amid Growing Demand for Nociscan.

The post Aclarion Grants Inducement Stock Option to New Western U.S. Commercial Director Amid Growing Demand for Nociscan appeared first on citybuzz.